Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced positive topline results from its pivotal Launch-HTN Phase 3 and ...

Scientists have identified a widely prescribed hypertension drug as a potential key to extending lifespan and slowing aging.

Among patients with isolated systolic hypertension and frailty, antihypertensive therapy is associated with improved outcomes.

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...

Mineralys Therapeutics’s oral hypertension therapy, lorundrostat, has met the primary endpoint in two pivotal studies, ...

Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of ...

Two pivotal trials of the aldosterone synthase inhibitor have shown positive results for lorundrostat in uncontrolled and ...

Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met ...

Lorundrostat is an orally-administered highly selective aldosterone synthase inhibitor that reduces aldosterone levels by inhibiting CYP11B2. The Launch-HTN trial (ClinicalTrials.gov Identifier: ...

The Launch-HTN trial evaluated lorundrostat as an add-on therapy to an existing, prescribed background treatment of two-to-five anti-hypertensive medications, while the Advance-HTN trial evaluated the ...